JP2002524463A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002524463A5 JP2002524463A5 JP2000568853A JP2000568853A JP2002524463A5 JP 2002524463 A5 JP2002524463 A5 JP 2002524463A5 JP 2000568853 A JP2000568853 A JP 2000568853A JP 2000568853 A JP2000568853 A JP 2000568853A JP 2002524463 A5 JP2002524463 A5 JP 2002524463A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- compound
- aryl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 185
- -1 perhaloalkyl Chemical group 0.000 description 99
- 125000003118 aryl group Chemical group 0.000 description 97
- 125000000217 alkyl group Chemical group 0.000 description 91
- 125000004093 cyano group Chemical group *C#N 0.000 description 61
- 125000001072 heteroaryl group Chemical group 0.000 description 61
- 125000005843 halogen group Chemical group 0.000 description 54
- 125000003710 aryl alkyl group Chemical group 0.000 description 46
- 125000004429 atom Chemical group 0.000 description 46
- 125000003107 substituted aryl group Chemical group 0.000 description 44
- 239000003814 drug Substances 0.000 description 42
- 229940124597 therapeutic agent Drugs 0.000 description 42
- 125000004432 carbon atom Chemical group C* 0.000 description 41
- 239000000651 prodrug Substances 0.000 description 35
- 229940002612 prodrug Drugs 0.000 description 35
- 150000003839 salts Chemical class 0.000 description 35
- 125000005842 heteroatom Chemical group 0.000 description 34
- 125000002723 alicyclic group Chemical group 0.000 description 31
- 229910052698 phosphorus Inorganic materials 0.000 description 27
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 25
- 125000001543 furan-2,5-diyl group Chemical group O1C(=CC=C1*)* 0.000 description 21
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 19
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 19
- 239000011574 phosphorus Substances 0.000 description 19
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 17
- 125000003545 alkoxy group Chemical group 0.000 description 17
- 125000006366 methylene oxy carbonyl group Chemical group [H]C([H])([*:1])OC([*:2])=O 0.000 description 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 16
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- 229910052736 halogen Inorganic materials 0.000 description 15
- 150000002367 halogens Chemical class 0.000 description 15
- 125000003342 alkenyl group Chemical group 0.000 description 14
- 125000000304 alkynyl group Chemical group 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 14
- 101710099475 3'-phosphoadenosine 5'-phosphate phosphatase Proteins 0.000 description 13
- 101710196411 Fructose-1,6-bisphosphatase Proteins 0.000 description 13
- 101710186733 Fructose-1,6-bisphosphatase, chloroplastic Proteins 0.000 description 13
- 101710109119 Fructose-1,6-bisphosphatase, cytosolic Proteins 0.000 description 13
- 101710198902 Fructose-1,6-bisphosphate aldolase/phosphatase Proteins 0.000 description 13
- 125000004423 acyloxy group Chemical group 0.000 description 13
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 13
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 8
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 8
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 125000004437 phosphorous atom Chemical group 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 6
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 6
- 125000006165 cyclic alkyl group Chemical group 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 4
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 4
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 4
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 4
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 4
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 4
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 4
- 208000002705 Glucose Intolerance Diseases 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 4
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 125000001786 isothiazolyl group Chemical group 0.000 description 4
- 125000000842 isoxazolyl group Chemical group 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- 201000009104 prediabetes syndrome Diseases 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 125000002098 pyridazinyl group Chemical group 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 125000000168 pyrrolyl group Chemical group 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 3
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 125000005741 alkyl alkenyl group Chemical group 0.000 description 3
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 2
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- 102000012195 Fructose-1,6-bisphosphatases Human genes 0.000 description 2
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 230000009229 glucose formation Effects 0.000 description 2
- 208000007345 glycogen storage disease Diseases 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 125000005343 heterocyclic alkyl group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13550498P | 1998-09-09 | 1998-09-09 | |
| US60/135,504 | 1998-09-09 | ||
| US11107798P | 1998-12-07 | 1998-12-07 | |
| US60/111,077 | 1998-12-07 | ||
| PCT/US1999/020346 WO2000014095A1 (en) | 1998-09-09 | 1999-09-03 | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002524463A JP2002524463A (ja) | 2002-08-06 |
| JP2002524463A5 true JP2002524463A5 (enExample) | 2006-10-19 |
Family
ID=26808618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000568853A Pending JP2002524463A (ja) | 1998-09-09 | 1999-09-03 | フルクトース−１，６−ビスホスファターゼの新規な芳香族インヒビター |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US6489476B1 (enExample) |
| EP (1) | EP1112275B9 (enExample) |
| JP (1) | JP2002524463A (enExample) |
| KR (2) | KR20070053264A (enExample) |
| CN (1) | CN1215076C (enExample) |
| AT (1) | ATE246197T1 (enExample) |
| AU (1) | AU761267C (enExample) |
| BR (1) | BR9913532A (enExample) |
| CA (1) | CA2343027A1 (enExample) |
| CZ (1) | CZ297264B6 (enExample) |
| DE (1) | DE69910045T2 (enExample) |
| DK (1) | DK1112275T3 (enExample) |
| ES (1) | ES2204170T3 (enExample) |
| HK (1) | HK1042496B (enExample) |
| HU (1) | HUP0103143A3 (enExample) |
| NO (1) | NO20011174L (enExample) |
| NZ (1) | NZ510308A (enExample) |
| PL (1) | PL205184B1 (enExample) |
| PT (1) | PT1112275E (enExample) |
| SK (1) | SK286080B6 (enExample) |
| WO (1) | WO2000014095A1 (enExample) |
Families Citing this family (150)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6284748B1 (en) * | 1997-03-07 | 2001-09-04 | Metabasis Therapeutics, Inc. | Purine inhibitors of fructose 1,6-bisphosphatase |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| DE69910045T2 (de) * | 1998-09-09 | 2004-04-22 | Metabasis Therapeutics Inc., San Diego | Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren |
| US6756360B1 (en) * | 1998-12-24 | 2004-06-29 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
| EP1724276A1 (en) * | 1999-03-05 | 2006-11-22 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing prodrugs |
| US7205404B1 (en) * | 1999-03-05 | 2007-04-17 | Metabasis Therapeutics, Inc. | Phosphorus-containing prodrugs |
| GB9923078D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| CZ301401B6 (cs) | 1999-12-22 | 2010-02-17 | Metabasis Therapeutics, Inc. | Bisamidátfosfonátová predléciva a farmaceutické prostredky s jejich obsahem |
| JP2003520226A (ja) | 2000-01-21 | 2003-07-02 | ノバルティス アクチエンゲゼルシャフト | ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物 |
| ATE350385T1 (de) | 2000-03-08 | 2007-01-15 | Metabasis Therapeutics Inc | Neue aryl fructose-1,6-bisphosphatase inhibitoren |
| US7563774B2 (en) * | 2000-06-29 | 2009-07-21 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| NZ523227A (en) * | 2000-07-06 | 2005-04-29 | Metabasis Therapeutics Inc | A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| US20070129334A1 (en) * | 2001-10-30 | 2007-06-07 | Conforma Therapeutics Corporation | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 |
| US7193081B2 (en) * | 2002-05-13 | 2007-03-20 | Metabasis Therapeutics, Inc. | Process for preparation of cyclic prodrugs of PMEA and PMPA |
| WO2004037161A2 (en) * | 2002-05-13 | 2004-05-06 | Metabasis Therapeutics, Inc. | Cyclic prodrugs of pmea one of its analogues |
| EP1535630A1 (en) * | 2002-07-23 | 2005-06-01 | Sankyo Company, Limited | Preventive for the onset of diabetes |
| WO2004041837A1 (en) * | 2002-10-31 | 2004-05-21 | Metabasis Therapeutics, Inc. | Novel cytarabine monophosphate prodrugs |
| US20040122067A1 (en) * | 2002-12-20 | 2004-06-24 | Lin Zhao | Treatment of chronic heart failure |
| US20040254228A1 (en) * | 2002-12-20 | 2004-12-16 | Lin Zhao | Treatment of chronic heart failure |
| US7705027B2 (en) * | 2003-02-11 | 2010-04-27 | Vernalis (Cambridge) Limited | Isoxazole compounds as inhibitors of heat shock proteins |
| WO2005051298A2 (en) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| US7129049B2 (en) * | 2003-12-22 | 2006-10-31 | Regents Of The University Of Minnesota | Method of detecting equine glycogen storage disease IV |
| ES2629414T3 (es) * | 2003-12-26 | 2017-08-09 | Kyowa Hakko Kirin Co., Ltd. | Derivados de tiazol |
| US7179827B2 (en) * | 2004-03-31 | 2007-02-20 | Lexicon Genetics Incorporated | Thiazoles and methods of their use |
| JP2007261945A (ja) * | 2004-04-07 | 2007-10-11 | Taisho Pharmaceut Co Ltd | チアゾール誘導体 |
| EP1753762B1 (en) * | 2004-06-08 | 2014-03-19 | Metabasis Therapeutics, Inc. | Lewis acid mediated synthesis of cyclic esters |
| EP1778250A2 (en) * | 2004-08-18 | 2007-05-02 | Metabasis Therapeutics, Inc. | Novel thiazole inhibitors of fructose 1,6-bisphosphatase |
| KR20070086007A (ko) * | 2004-12-13 | 2007-08-27 | 다이이찌 산쿄 가부시키가이샤 | 당뇨병의 치료를 위한 의약 조성물 |
| KR20070086137A (ko) * | 2004-12-15 | 2007-08-27 | 다이이찌 산쿄 가부시키가이샤 | ＦＢＰａｓｅ 저해제를 함유하는 의약 조성물 |
| WO2008134474A2 (en) | 2007-04-27 | 2008-11-06 | The Board Of Trustees Of The University Of Illinois | Compositions and methods including cell death inducers and procaspase activation |
| JPWO2006137527A1 (ja) | 2005-06-23 | 2009-01-22 | 協和発酵キリン株式会社 | チアゾール誘導体 |
| FR2889190A1 (fr) * | 2005-08-01 | 2007-02-02 | Merck Sante Soc Par Actions Si | Nouveaux derives d'imidazoles carboxamides comme inhibiteurs de fructose -1,6-biphosphatase et compositions pharmaceutiques les contenant |
| EP1752450A1 (en) | 2005-08-01 | 2007-02-14 | Merck Sante | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them |
| CN102935081B (zh) | 2005-09-14 | 2015-03-04 | 武田药品工业株式会社 | 用于治疗糖尿病的二肽基肽酶抑制剂 |
| CN101489380A (zh) | 2006-05-19 | 2009-07-22 | 伊利诺伊大学评议会 | 用于治疗黑素瘤和其他癌症的含三苯基甲基膦酸酯的含磷化合物 |
| WO2008063842A2 (en) | 2006-11-02 | 2008-05-29 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain with agonists of ppar-gamma |
| US20080218127A1 (en) * | 2007-03-07 | 2008-09-11 | O2Micro Inc. | Battery management systems with controllable adapter output |
| US7973515B2 (en) * | 2007-03-07 | 2011-07-05 | O2Micro, Inc | Power management systems with controllable adapter output |
| US8222870B2 (en) * | 2007-03-07 | 2012-07-17 | O2Micro, Inc | Battery management systems with adjustable charging current |
| JP5572549B2 (ja) | 2007-08-13 | 2014-08-13 | リガンド・ファーマシューティカルズ・インコーポレイテッド | グルコキナーゼの新規な活性化剤 |
| EP2058308A1 (fr) | 2007-11-12 | 2009-05-13 | Merck Sante | Dérivés de benzimidazoledihydrothiadiazinone comme inhibiteurs de fructose-1,6-biphosphatase et compositions pharmaceutiques les contenant. |
| US8111038B2 (en) * | 2008-06-12 | 2012-02-07 | O2 Micro, Inc | Vehicle electronic systems with battery management functions |
| US8394969B2 (en) * | 2008-09-26 | 2013-03-12 | Merck Sharp & Dohme Corp. | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| JP2012507530A (ja) | 2008-10-29 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病剤である新規な環状ベンズイミダゾール誘導体 |
| EP2362731B1 (en) | 2008-10-31 | 2016-04-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
| WO2010056717A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
| WO2010091382A1 (en) | 2009-02-09 | 2010-08-12 | The Board Of Trustees Of The University Of Illinois | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs |
| US20120046364A1 (en) | 2009-02-10 | 2012-02-23 | Metabasis Therapeutics, Inc. | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use |
| DK3366686T3 (da) | 2009-03-20 | 2020-11-23 | Metabasis Therapeutics Inc | Inhibitorer af diacylglycerol-o-acyltransferase 1 (dgat-1) og anvendelser deraf |
| WO2011011508A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011019538A1 (en) | 2009-08-13 | 2011-02-17 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| IN2012DN00721A (enExample) | 2009-09-02 | 2015-06-19 | Merck Sharp & Dohme | |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| WO2011097079A1 (en) | 2010-02-03 | 2011-08-11 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
| EP2538783B1 (en) | 2010-02-22 | 2016-06-01 | Merck Sharp & Dohme Corp. | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| EP2571876B1 (en) | 2010-05-21 | 2016-09-07 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| WO2012024183A1 (en) | 2010-08-18 | 2012-02-23 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
| BR112013020975A2 (pt) * | 2011-02-24 | 2016-10-11 | Jiangsu Hansoh Pharmaceutical Co Ltd | compostos contendo fósforo como inibidores de proteína quinases |
| SG192941A1 (en) | 2011-02-25 | 2013-09-30 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| US8957062B2 (en) | 2011-04-08 | 2015-02-17 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| US20140088124A1 (en) | 2011-06-02 | 2014-03-27 | Robert J. DeVita | Imidazole derivatives |
| WO2012173917A1 (en) | 2011-06-16 | 2012-12-20 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment |
| EP2760855B1 (en) | 2011-09-30 | 2017-03-15 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes |
| US9018200B2 (en) | 2011-10-24 | 2015-04-28 | Merck Sharp & Dohme Corp. | Substituted piperidinyl compounds useful as GPR119 agonists |
| WO2013068328A1 (en) | 2011-11-07 | 2013-05-16 | Intervet International B.V. | Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors |
| WO2013068439A1 (en) | 2011-11-09 | 2013-05-16 | Intervet International B.V. | 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors |
| WO2013074581A1 (en) * | 2011-11-15 | 2013-05-23 | Weihua Zhang | Fructose-1,6-biphosphatases as new targets for diagnosing and treating breast cancer brain metastasis |
| US9018224B2 (en) | 2011-11-15 | 2015-04-28 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as GPR119 agonists |
| WO2013122920A1 (en) | 2012-02-17 | 2013-08-22 | Merck Sharp & Dohme Corp. | Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| CA2870488A1 (en) | 2012-04-16 | 2013-10-24 | Kaneq Pharma Inc. | Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors |
| EP2874622A4 (en) | 2012-07-23 | 2015-12-30 | Merck Sharp & Dohme | TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS |
| WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US9556193B2 (en) | 2012-08-22 | 2017-01-31 | Merck Shapr & Dohme Corp. | Benzimidazole hexahydrofuro[3,2-b]furan derivatives |
| US9527839B2 (en) | 2012-08-22 | 2016-12-27 | Merck Sharp & Dohme Corp. | Benzimidazole tetrahydropyran derivatives |
| WO2014031517A1 (en) | 2012-08-22 | 2014-02-27 | Merck Sharp & Dohme Corp. | Novel azabenzimidazole tetrahydrofuran derivatives |
| EP2888006B1 (en) | 2012-08-22 | 2019-04-24 | Merck Sharp & Dohme Corp. | Novel azabenzimidazole tetrahydropyran derivatives useful as ampk activators |
| KR20150045436A (ko) | 2012-08-22 | 2015-04-28 | 머크 샤프 앤드 돔 코포레이션 | 신규 아자벤즈이미다졸 헥사히드로푸로[3,2-b]푸란 유도체 |
| WO2014031441A1 (en) | 2012-08-22 | 2014-02-27 | Merck Sharp & Dohme Corp. | Novel benzimidazole tetrahydrofuran derivatives |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| US9453038B2 (en) | 2012-12-17 | 2016-09-27 | Merck Sharp & Dohme Corp. | Glucokinase activator compounds, compositions containing such compounds, and methods of treatment |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US10519115B2 (en) | 2013-11-15 | 2019-12-31 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
| WO2015112465A1 (en) | 2014-01-24 | 2015-07-30 | Merck Sharp & Dohme Corp. | Isoquinoline derivatives as mgat2 inhibitors |
| EP3623364A1 (en) | 2014-02-13 | 2020-03-18 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
| EP3110805B1 (en) | 2014-02-25 | 2019-12-11 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of complement mediated disorders |
| WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| CN106687118A (zh) | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
| WO2016022742A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2016022448A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10100042B2 (en) | 2014-08-08 | 2018-10-16 | Merck Sharp & Dohme Corp. | [5,6]—fused bicyclic antidiabetic compounds |
| CA2964379C (en) | 2014-10-24 | 2023-08-15 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and glp-1 receptors |
| EA036985B1 (ru) | 2014-10-31 | 2021-01-25 | НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. | Композиции и способы лечения метаболических расстройств |
| TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
| WO2016191334A1 (en) | 2015-05-27 | 2016-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
| US10213429B2 (en) | 2015-05-28 | 2019-02-26 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| US10385097B2 (en) | 2015-08-26 | 2019-08-20 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
| WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035357A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
| WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| JP2018528254A (ja) * | 2015-09-22 | 2018-09-27 | バイキング セラピューティクス，インコーポレーテッド | グルコース産生阻害物質との併用療法 |
| WO2017062334A1 (en) | 2015-10-05 | 2017-04-13 | Merck Sharp & Dohme Corp. | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors |
| EP3383868B1 (en) | 2015-11-30 | 2022-10-05 | Merck Sharp & Dohme LLC | Aryl sulfonamides as blt1 antagonists |
| WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
| WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
| WO2017201683A1 (en) | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists |
| US10414774B2 (en) | 2016-08-15 | 2019-09-17 | Merck Sharp & Dohme Corp. | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease |
| EP3496715B1 (en) | 2016-08-15 | 2021-11-03 | Merck Sharp & Dohme Corp. | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease |
| WO2018057409A1 (en) | 2016-09-20 | 2018-03-29 | Merck Sharp & Dohme Corp. | Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as pcsk9 allosteric binders |
| RU2019117958A (ru) | 2016-11-18 | 2020-12-18 | Мерк Шарп И Доум Корп. | Производные индола, полезные в качестве ингибиторов диацилглицерид-о-ацилтрансферазы 2 |
| CA3043203A1 (en) | 2016-11-18 | 2018-05-24 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
| WO2018107415A1 (en) | 2016-12-15 | 2018-06-21 | Merck Sharp & Dohme Corp. | Hydroxy isoxazole compounds useful as gpr120 agonists |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| WO2018175670A1 (en) | 2017-03-22 | 2018-09-27 | The Research Foundation For The State University Of New York | Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same |
| EP3661493A4 (en) | 2017-08-02 | 2021-04-14 | Achillion Pharmaceuticals, Inc. | TREATMENT DIET FOR THE TREATMENT OF PAROXYSTIC NOCTURAL HEMOGLOBINURIA |
| US11970482B2 (en) | 2018-01-09 | 2024-04-30 | Ligand Pharmaceuticals Inc. | Acetal compounds and therapeutic uses thereof |
| JOP20190150A1 (ar) | 2018-06-21 | 2019-12-21 | Merck Sharp & Dohme | مركبات مناهضة لـ pcsk9 |
| EP3846803A4 (en) | 2018-09-06 | 2022-08-10 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| EP3847174A4 (en) | 2018-09-06 | 2022-06-15 | Achillion Pharmaceuticals, Inc. | MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS |
| CA3114039A1 (en) | 2018-09-25 | 2020-04-02 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| KR20210104071A (ko) | 2018-12-17 | 2021-08-24 | 아칠리온 파르마세우티칼스 인코포레이티드 | 보체 매개 장애의 치료를 위한 표적 투약 |
| MX2021011507A (es) | 2019-03-22 | 2021-12-15 | Achillion Pharmaceuticals Inc | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. |
| KR102691198B1 (ko) | 2019-03-28 | 2024-08-05 | 백동민 | 로봇청소기 및 그 제어방법 |
| WO2020205688A1 (en) | 2019-04-04 | 2020-10-08 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes |
| TW202123960A (zh) | 2019-08-30 | 2021-07-01 | 美商默沙東藥廠 | Pcsk9拮抗劑化合物 |
| EP3842061A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled triazole co-agonists of the glucagon and glp-1 receptors |
| EP3842060A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled lactam co-agonists of the glucagon and glp-1 receptors |
| EP3842449A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled olefin co-agonists of the glucagon and glp-1 receptors |
| EP4153584A1 (en) | 2020-05-18 | 2023-03-29 | Merck Sharp & Dohme LLC | Novel diacylglyceride o-acyltransferase 2 inhibitors |
| CR20230160A (es) | 2020-10-08 | 2023-06-02 | Merck Sharp & Dohme Llc | Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 |
| MX2023003842A (es) | 2020-10-08 | 2023-04-14 | Merck Sharp & Dohme Llc | Preparacion de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2. |
| MX2024002146A (es) | 2021-08-19 | 2024-03-08 | Merck Sharp & Dohme Llc | Compuestos para el tratamiento de afecciones relacionadas con la actividad de pcsk9. |
| US20230406885A1 (en) | 2022-06-15 | 2023-12-21 | Merck Sharp & Dohme Llc | Cyclic peptides for trapping interleukin-1 beta |
| KR20250107282A (ko) | 2022-12-02 | 2025-07-11 | 머크 샤프 앤드 돔 엘엘씨 | 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의 융합된 아졸 유도체의 제조 |
| WO2025106386A1 (en) | 2023-11-14 | 2025-05-22 | Merck Sharp & Dohme Llc | A cyclic peptide for trapping interleukin-1 beta |
| WO2025128805A1 (en) | 2023-12-15 | 2025-06-19 | Merck Sharp & Dohme Llc | A cyclic peptide il-1beta trap for the treatment of atherosclerosis and inflammatory disorders |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR34480E (enExample) | 1929-01-17 | 1929-06-19 | ||
| US3551422A (en) | 1968-03-27 | 1970-12-29 | Stevens & Co Inc J P | N-(oxymethyl) derivatives of phosphonopolyamino-s-triazines |
| US3657282A (en) | 1969-01-23 | 1972-04-18 | Merck & Co Inc | Carboxyepoxyethyl-1-phosphonic acid and derivatives |
| US3822296A (en) | 1969-01-23 | 1974-07-02 | Merck & Co Inc | 1-trifluoromethyl-1,2-epoxyethyl-1-phosphonic acid and its salts |
| GB1343022A (en) | 1970-04-19 | 1974-01-10 | British Oxygen Co Ltd | Phosphorus-containing guanamines |
| GB1428137A (en) | 1972-09-27 | 1976-03-17 | Ici Ltd | Prostanoic acid derivatives |
| US4000305A (en) | 1972-09-27 | 1976-12-28 | Imperial Chemical Industries Limited | 15-, 16- AND 17-Indolyl or indolinyl nor prostanoic acid derivatives |
| GB1516347A (en) | 1975-09-16 | 1978-07-05 | Ici Ltd | Process for the preparation of alkylphosphonate esters |
| US4092323A (en) | 1975-09-16 | 1978-05-30 | Imperial Chemical Industries Limited | Hydrazine derivatives of pyridyl-ketones |
| DE2855659A1 (de) | 1978-12-22 | 1980-07-03 | Bayer Ag | Benzimidazolyl-2-alkan-phosphonsaeuren |
| EP0033195B1 (en) | 1980-01-10 | 1985-12-04 | NYEGAARD & CO. A/S | Pyrimidine-2-sulphides and their s-oxides for use in medicine, pharmaceutical compositions containing them, processes for their preparation and such compounds when novel per se |
| FR2531088B1 (fr) | 1982-07-29 | 1987-08-28 | Sanofi Sa | Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation |
| IL77243A (en) | 1984-12-21 | 1996-11-14 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds |
| US4902679A (en) | 1985-12-13 | 1990-02-20 | Norwich Eaton Pharmaceuticals, Inc. | Methods of treating diseases with certain geminal diphosphonates |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| ES2039237T3 (es) | 1986-04-24 | 1993-09-16 | Fujisawa Pharmaceutical Co., Ltd. | Procedimiento para preparar nuevos compuestos de acido difosfonico. |
| JPS636089A (ja) | 1986-06-27 | 1988-01-12 | Nippon Shokubai Kagaku Kogyo Co Ltd | 石炭−水スラリ−用分散剤 |
| US5091552A (en) | 1986-06-30 | 1992-02-25 | Board Of Regents, The University Of Texas System | Novel antitumor aldophosphamide analogs |
| IL84497A (en) | 1986-11-21 | 1994-10-21 | Ciba Geigy Ag | 2-(Imidazol-1-yl) ethane-1,1-diphosphonic acid derivatives, their preparation and pharmaceutical compositions containing them |
| JPS63250290A (ja) | 1987-04-06 | 1988-10-18 | Matsushita Electric Ind Co Ltd | 電子スチルカメラ |
| US4912175A (en) | 1988-08-01 | 1990-03-27 | E. I. Du Pont De Nemours And Company | Process for in creasing polyamide molecular weight with P containing catalyst |
| US4968790A (en) | 1988-08-12 | 1990-11-06 | American Cyanamid Company | Antidiabetic phosphates |
| US4943629A (en) * | 1988-08-12 | 1990-07-24 | American Cyanamid Company | Antidiabetic alpha-substituted phosphonates |
| FI904694A0 (fi) * | 1989-01-24 | 1990-09-24 | Gensia Pharma | Foerfarande och foereningar foer ingivning av aica-ribosiden och saenkning av glukos i blodet. |
| US5658889A (en) | 1989-01-24 | 1997-08-19 | Gensia Pharmaceuticals, Inc. | Method and compounds for aica riboside delivery and for lowering blood glucose |
| MX21452A (es) | 1989-07-07 | 1994-01-31 | Ciba Geigy Ag | Preparaciones farmaceuticas que se administran en forma topica. |
| DE4029444A1 (de) | 1989-09-19 | 1991-03-28 | Ciba Geigy Ag | Phosphonyl-enamine als pflanzenwuchsregulatoren |
| EP0438375B1 (de) | 1990-01-18 | 1995-12-27 | Ciba-Geigy Ag | Phoshponsäure- und Thionophosphonsäure-Derivate |
| US5116919A (en) | 1990-12-05 | 1992-05-26 | E. I. Du Pont De Nemours And Company | Process for increasing the relative viscosity of polyamides with reduced thermal degradation |
| FI89366C (fi) | 1990-12-20 | 1993-09-27 | Leiras Oy | Foerfarande foer framstaellning av nya farmakologiskt anvaendbara metylenbisfosfonsyraderivat |
| US5194616A (en) | 1991-01-24 | 1993-03-16 | E. I. Du Pont De Nemours And Company | Preparation of 2-(pyridyl)ethyl bis-(trialkyl silyl)phosphonate derivatives |
| WO1992019629A1 (en) | 1991-04-27 | 1992-11-12 | Japat Ltd. | Triazole compounds |
| EP0528760A1 (en) | 1991-08-09 | 1993-02-24 | Japat Ltd | Novel triazoles |
| US5142000A (en) | 1991-08-28 | 1992-08-25 | E. I. Du Pont De Nemours And Company | Process for increasing polyamide molecular weight with organophosphonic acid or ester catalysts in the presence of alumina-containing titanium dioxide |
| US5302586A (en) | 1991-12-19 | 1994-04-12 | G. D. Searle & Co. | Phosphonomethyl-imidazo[1,2-a]pyrimidine-2-carboxylic acid compounds for treatment of neurotoxic injury |
| MX9300141A (es) | 1992-01-13 | 1994-07-29 | Smithkline Beecham Corp | Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. |
| GB9202779D0 (en) | 1992-02-10 | 1992-03-25 | Ici Plc | Novel compounds |
| CH683996A5 (fr) | 1992-03-05 | 1994-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et compositions pharmaceutiques les contenant. |
| US5731299A (en) | 1992-05-29 | 1998-03-24 | The Procter & Gamble Company | Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
| JP2787407B2 (ja) | 1992-06-19 | 1998-08-20 | 株式会社大塚製薬工場 | ホスホン酸ジエステル誘導体 |
| JP2789134B2 (ja) | 1992-09-28 | 1998-08-20 | ファイザー・インク． | 糖尿病の合併症を制御する置換ピリミジン類 |
| GB2271113A (en) | 1992-10-02 | 1994-04-06 | Japat Ltd | Triazolyl alkyl phosphates or phosphonates |
| DE4303648A1 (de) | 1993-02-09 | 1994-08-11 | Basf Ag | Verwendung von Aminovinylphosphonsäureestern als Lichtschutzmittel und Stabilisatoren für organisches Material |
| JPH06298779A (ja) | 1993-04-15 | 1994-10-25 | Hoechst Japan Ltd | ヘテロ環イミノビスメチレンビスホスホン酸誘導体 |
| ATE199906T1 (de) | 1993-06-29 | 2001-04-15 | Mitsubishi Chem Corp | Phosphonat-nukleotid ester-derivate |
| IT1266570B1 (it) | 1993-07-30 | 1997-01-09 | Zambon Spa | Derivati della propanammide n-eteroaril sostituiti utili nel trattamento delle malattie cardiovascolari |
| AU691527B2 (en) | 1993-09-17 | 1998-05-21 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5728650A (en) | 1993-10-07 | 1998-03-17 | Zeneca Limited | Herbicidal aza bisphosphonic acids and compositions containing the same |
| GB9324143D0 (en) | 1993-11-24 | 1994-01-12 | Schering Agrochemicals Ltd | Triazole phosphonate pesticides |
| DE19501843A1 (de) | 1994-12-16 | 1996-06-20 | Bayer Ag | Substituierte Sulfonylharnstoffe |
| JP3500468B2 (ja) | 1995-12-27 | 2004-02-23 | 株式会社大塚製薬工場 | ホスホン酸ジエステル誘導体 |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US6011049A (en) | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
| EP0970095B1 (en) | 1997-03-07 | 2003-10-29 | Metabasis Therapeutics, Inc. | Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase |
| AU6691798A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| US6284748B1 (en) | 1997-03-07 | 2001-09-04 | Metabasis Therapeutics, Inc. | Purine inhibitors of fructose 1,6-bisphosphatase |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| AU767599B2 (en) | 1998-03-06 | 2003-11-20 | Metabasis Therapeutics, Inc. | Novel prodrugs for phosphorus-containing compounds |
| EP1070084A4 (en) | 1998-03-16 | 2001-09-12 | Ontogen Corp | PIPERAZINE AS INHIBITORS OF FRUKTOSE-1,6-BISPHOSPHATASE (FBPASE) |
| DE69910045T2 (de) | 1998-09-09 | 2004-04-22 | Metabasis Therapeutics Inc., San Diego | Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren |
| EP1143955B1 (en) | 1998-12-24 | 2005-07-27 | Metabasis Therapeutics, Inc. | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
| US6756360B1 (en) | 1998-12-24 | 2004-06-29 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
| US6284672B1 (en) | 1999-03-02 | 2001-09-04 | Advanced Micro Devices, Inc. | Method of forming a super-shallow amorphous layer in silicon |
| CZ301401B6 (cs) | 1999-12-22 | 2010-02-17 | Metabasis Therapeutics, Inc. | Bisamidátfosfonátová predléciva a farmaceutické prostredky s jejich obsahem |
| JP2003520226A (ja) | 2000-01-21 | 2003-07-02 | ノバルティス アクチエンゲゼルシャフト | ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物 |
| ATE350385T1 (de) | 2000-03-08 | 2007-01-15 | Metabasis Therapeutics Inc | Neue aryl fructose-1,6-bisphosphatase inhibitoren |
| US7563774B2 (en) | 2000-06-29 | 2009-07-21 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| NZ523227A (en) | 2000-07-06 | 2005-04-29 | Metabasis Therapeutics Inc | A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| EP1778250A2 (en) | 2004-08-18 | 2007-05-02 | Metabasis Therapeutics, Inc. | Novel thiazole inhibitors of fructose 1,6-bisphosphatase |
-
1999
- 1999-09-03 DE DE69910045T patent/DE69910045T2/de not_active Expired - Lifetime
- 1999-09-03 CA CA002343027A patent/CA2343027A1/en not_active Abandoned
- 1999-09-03 HK HK02104187.3A patent/HK1042496B/zh not_active IP Right Cessation
- 1999-09-03 SK SK316-2001A patent/SK286080B6/sk not_active IP Right Cessation
- 1999-09-03 US US09/389,698 patent/US6489476B1/en not_active Expired - Lifetime
- 1999-09-03 EP EP99954595A patent/EP1112275B9/en not_active Expired - Lifetime
- 1999-09-03 AU AU10905/00A patent/AU761267C/en not_active Ceased
- 1999-09-03 WO PCT/US1999/020346 patent/WO2000014095A1/en not_active Ceased
- 1999-09-03 AT AT99954595T patent/ATE246197T1/de active
- 1999-09-03 PL PL346520A patent/PL205184B1/pl not_active IP Right Cessation
- 1999-09-03 KR KR1020077006087A patent/KR20070053264A/ko not_active Ceased
- 1999-09-03 ES ES99954595T patent/ES2204170T3/es not_active Expired - Lifetime
- 1999-09-03 HU HU0103143A patent/HUP0103143A3/hu unknown
- 1999-09-03 JP JP2000568853A patent/JP2002524463A/ja active Pending
- 1999-09-03 CN CNB998130362A patent/CN1215076C/zh not_active Expired - Fee Related
- 1999-09-03 KR KR1020017003079A patent/KR100818845B1/ko not_active Expired - Lifetime
- 1999-09-03 BR BR9913532-9A patent/BR9913532A/pt not_active Application Discontinuation
- 1999-09-03 CZ CZ20010840A patent/CZ297264B6/cs not_active IP Right Cessation
- 1999-09-03 DK DK99954595T patent/DK1112275T3/da active
- 1999-09-03 PT PT99954595T patent/PT1112275E/pt unknown
- 1999-09-03 NZ NZ510308A patent/NZ510308A/xx not_active IP Right Cessation
-
2001
- 2001-03-07 NO NO20011174A patent/NO20011174L/no not_active Application Discontinuation
-
2003
- 2003-08-06 US US10/636,474 patent/US7312219B2/en not_active Expired - Fee Related
-
2007
- 2007-04-30 US US11/742,023 patent/US20070232571A1/en not_active Abandoned
- 2007-08-20 US US11/842,035 patent/US20080015195A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002524463A5 (enExample) | ||
| JP2003519154A5 (enExample) | ||
| EP1240174A2 (en) | Novel bisamidate phosphonate prodrugs | |
| JP5588040B2 (ja) | Ｓ１ｐ１／ｅｄｇ１受容体アゴニストとしてのアミノ−ピリジン誘導体 | |
| JP2010536773A5 (enExample) | ||
| JP2003515523A5 (enExample) | ||
| EP2650287B9 (en) | Thiazole Derivative and use thereof as VAP-1 Inhibitor | |
| JP2007512359A5 (enExample) | ||
| JP2015526448A5 (enExample) | ||
| US8501793B2 (en) | Blood flow promoters for cauda equina tissues | |
| JP2013532652A5 (enExample) | ||
| JP2018526399A5 (enExample) | ||
| JP2007502264A5 (enExample) | ||
| JP2012530713A5 (enExample) | ||
| RU2001120726A (ru) | Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета | |
| JP2008528520A5 (enExample) | ||
| JP6261011B2 (ja) | 眼疾患処置薬 | |
| JPWO2020123827A5 (enExample) | ||
| JP2014500322A5 (enExample) | ||
| JP2011527345A5 (enExample) | ||
| ES2525298T3 (es) | Compuestos heterocíclicos como agonistas del S1P1 para el tratamiento de enfermedades autoinmunes y vasculares | |
| RU2006140989A (ru) | 2-пиридилзамещенные имидазолы как ингибиторы рецепторов alk4 | |
| ES2548258T3 (es) | Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1 | |
| WO2000015213A1 (en) | Remedal or preventive agent for congestive heart failure | |
| JPWO2019144041A5 (enExample) |